Acne marks or acne scars: the distinction changes the treatment completely

Post-acne marks versus acne scars: two different tissue changes

The term "acne scar" is commonly applied to two completely different tissue changes that have distinct causes and require distinct treatments. Post-inflammatory hyperpigmentation (PIH) — the flat, dark or red discolouration left after an acne lesion resolves — is a pigmentary change in the epidermis, not a structural scar. It occurs because the inflammation of the acne lesion activates melanocytes in the surrounding skin, which produce additional melanin that remains in keratinocytes as the lesion heals. PIH has no textural component and is at the same level as the surrounding skin when touched. True acne scars are structural changes in the dermis — atrophic scars (ice-pick, boxcar, rolling) represent permanent collagen and tissue loss from the dermis caused by the inflammatory destruction of the acne papule or cyst, while hypertrophic and keloid scars represent excess collagen deposition. PIH fades over months with appropriate care; true atrophic scars represent permanent tissue deficit that topical products cannot fill.

Why PIH responds to topical treatment but atrophic scars do not

PIH fades through two natural processes: cell turnover (melanin-containing keratinocytes migrate to the surface and are shed over twenty-eight to forty-two days, gradually replacing the pigmented cells with unpigmented new cells from below) and melanin dispersal (some melanin phagocytosed by macrophages is transported away from the skin surface over weeks). Topical brightening actives accelerate the natural fading by inhibiting melanin transfer (niacinamide), inhibiting tyrosinase production (vitamin C, kojic acid) and accelerating cell turnover (AHA exfoliation surfaces and sheds the pigmented cells faster). For atrophic scars, topical products cannot fill the tissue deficit — the dermis has permanently lost volume and collagen in the scar area. What topical PDRN and centella can do for atrophic scars is improve the surrounding dermal quality, partially stimulate collagen production within the scar tissue (reducing the depth contrast slightly over months), and maintain the best possible skin condition for the in-clinic treatments (microneedling, fractional laser, subcision) that are the primary interventions for true structural scars.

CICA ampoule for PIH prevention: treating the inflammation that causes pigmentation

The most effective intervention for PIH is prevention — reducing the inflammatory response of an active breakout reduces the melanocyte activation that produces PIH. A centella CICA ampoule applied daily to active and healing breakouts modulates the NF-κB inflammatory pathway that drives both the inflammatory lesion response and the downstream melanocyte activation. Madecassoside in the centella formula reduces the prostaglandin and cytokine production that signals melanocytes to increase melanin production. Applying the CICA ampoule during the active breakout phase (rather than waiting for the mark to appear) is more effective than applying brightening actives after PIH has already formed — the inflammatory-to-melanogenic signalling takes approximately seventy-two hours after lesion formation to produce visible pigmentation, giving a treatment window for intervention before PIH establishes.

The brightening cream for established PIH marks

Once PIH has formed, a multi-mechanism brightening cream addresses the established pigmentation through a combination of tyrosinase inhibition (reducing ongoing melanin production in the activated melanocytes), melanin transfer inhibition (niacinamide) and the accelerated cell turnover that morning AHA exfoliation provides. A melanon brightening cream applied in the evening over the PIH mark provides extended overnight contact between the brightening actives and the pigmented skin surface, while the cream's emollient base prevents the post-exfoliation TEWL that would otherwise slow the cell turnover from the previous evening's AHA. The combination of CICA for the inflammatory component and brightening cream for the established pigmentation covers both the driver (inflammation) and the outcome (melanin accumulation) of the PIH process.

Managing realistic expectations for PIH timeline and scar resolution

PIH on lighter skin tones typically fades significantly within four to eight weeks of appropriate topical treatment (AHA exfoliation twice weekly, daily niacinamide, daily SPF to prevent UV activation of residual melanocytes). On darker skin tones, the same PIH may take four to six months to fade because the higher baseline melanocyte activity produces a more significant initial PIH response and a slower natural fading process. True atrophic scars do not fade — they represent permanent dermal volume loss that is stable for decades once the initial remodelling phase is complete. For people managing both PIH and atrophic scars, the topical routine (centella, brightening actives, PDRN for surrounding skin quality) is the foundation, and in-clinic treatments (microneedling, laser, subcision for ice-pick and boxcar scars, filler for rolling scars) are the interventions for the structural component that topicals cannot address.